Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic...

Area of Science:

• Oncology
• Pharmacology

Background:

• Phosphatidylinositol 3-kinase-delta (PI3Kδ) signaling is crucial for malignant B-cell survival and proliferation.
• Idelalisib, a PI3Kδ inhibitor, has demonstrated efficacy as a single agent in chronic lymphocytic leukemia (CLL).

Purpose of the Study:

• To evaluate the safety and clinical activity of idelalisib in combination with bendamustine and/or rituximab in relapsed or refractory (R/R) CLL patients.
• To assess overall response rate (ORR), duration of response (DOR), and progression-free survival (PFS).

Main Methods:

• A Phase I/II study involving 52 heavily pretreated R/R CLL patients.
• Idelalisib administered continuously (100 or 150 mg BID) with bendamustine and/or rituximab for up to 6 cycles.
• Safety and efficacy endpoints were monitored, including adverse events and response rates.

Main Results:

• An overall response rate (ORR) of 84.6% was observed across combination arms (IR: 89.5%, IB: 77.8%, IBR: 86.7%).
• Median progression-free survival (PFS) was 25.6 months, and median duration of response (DOR) was 26.6 months.
• Common grade ≥3 adverse events included pneumonia (19.2%), febrile neutropenia (17.3%), and diarrhea (13.5%).

Conclusions:

• Idelalisib-based combinations demonstrate significant clinical activity and durable tumor control in R/R CLL.
• The observed tolerability profile necessitates cautious application of these regimens in this patient population.
• Further investigation into optimizing the risk-benefit ratio of idelalisib combinations in CLL is warranted.